Molloy A M, Ardill J, Tomkin G H
Diabetologia. 1980 Aug;19(2):93-6. doi: 10.1007/BF00421851.
Gastric acid secretion and gastrointestinal hormone levels were measured in healthy non-diabetic subjects after metformin treatment (1.5 g/day). The maximum acid output was increased from 15.7 +/- 3.9 mmol/h (mean +/- SEM) to 30.0 +/- 7.1 mmol/h (p < 0.05) and the peak acid output was increased from 16.4 +/- 4.1 mmol/h to 31.7 +/- 7.2 mmol/h (p < 0.05) after two weeks treatment. Serum insulin, gastric inhibitory polypeptide and secretin levels were normal. After treatment for one week, however, there was a significant increase in fasting vasoactive intestinal peptide (VIP) from 83 +/- 6 ng/1 to 102 +/- 9 ng/1 (p < 0.02) and in stimulated VIP from 58 +/- 5 ng/1 to 79 +/- 5 ng/1 (p < 0.05). Stimulated glucagon-like immunoreactivity (GLI) was also increased from 82 +/- 10 ng/1 to 174 +/- 24 ng/1 (p < 0.01) after one week's treatment. It is suggested that metformin acts as a weak histamine agonist.
在健康非糖尿病受试者接受二甲双胍治疗(1.5克/天)后,测定胃酸分泌和胃肠激素水平。治疗两周后,最大酸排量从15.7±3.9毫摩尔/小时(均值±标准误)增至30.0±7.1毫摩尔/小时(p<0.05),高峰酸排量从16.4±4.1毫摩尔/小时增至31.7±7.2毫摩尔/小时(p<0.05)。血清胰岛素、胃抑制多肽和促胰液素水平正常。然而,治疗一周后,空腹血管活性肠肽(VIP)从83±6纳克/升显著增至102±9纳克/升(p<0.02),刺激后VIP从58±5纳克/升增至79±5纳克/升(p<0.05)。治疗一周后,刺激后胰高血糖素样免疫反应性(GLI)也从82±10纳克/升增至174±24纳克/升(p<0.01)。提示二甲双胍起弱组胺激动剂的作用。